The abstract is read at the publisher; the summary is JClub's.
Five ongoing late-stage trials are testing biomarker-driven first-line regimens for advanced gastric and gastroesophageal junction adenocarcinoma, spanning HER2-, claudin-18.2-, chemotherapy-, and immune-checkpoint–directed combinations.
- Why it matters: Optimal first-line combinations and sequencing across these targeted and immune approaches remain uncertain, limiting how clinicians choose regimens for biomarker-defined patients.
- What they did: The review summarizes the rationale and prespecified designs of five distinct late-stage trials, each using different treatment backbones, biomarker-defined populations, and comparators.
- The result: The Trial Watch provides a structured guide to what these studies are designed to test, helping readers interpret emerging evidence without assuming results.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.